Niagen Bioscience, Inc. (NAGE)
NASDAQ:NAGE
Want to see NAGE full AI Analyst Report?
NAGE Stock Chart & Stats
$4.84
--
Market closed
$4.84
--
Day’s Range― - ―
52-Week Range$3.41 - $14.69
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.00M
Market Cap
$274.77M
Enterprise Value$243.45M
Total Cash (Recent Filing)$66.55M
Total Debt (Recent Filing)$2.58M
Price to Earnings (P/E)14.8
Beta0.97
Next Earnings
Aug 12, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.24
Shares Outstanding79,644,325
10 Day Avg. Volume979,982
30 Day Avg. Volume1,004,723
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)6.58
Price to Sales (P/S)3.89
P/FCF Ratio38.31
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue1.87
Enterprise Value/Gross Profit2.90
Enterprise Value/Ebitda18.21
Forecast
1Y Price Target
$11.25Price Target Upside132.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.23
Revenue Forecast (FY)$142.29M
Bulls Say, Bears Say
Bulls Say
High Gross Margins & Sustained ProfitabilityConsistently high gross margins and a return to multi-year profitability provide durable cash flow and pricing flexibility. For a supplements/ingredient business, strong gross margins support reinvestment in marketing, R&D, and channel expansion while absorbing customer/channel timing volatility.
Conservative Balance Sheet And Ample CashA low-leverage balance sheet with substantial cash gives strategic optionality: fund product launches, increased marketing, share repurchases, or M&A without financing stress. This financial flexibility reduces execution risk during industry/regulatory cycles.
Quality Differentiation & Product DiversificationA USP monograph and new delivery formats (at-home injections, telehealth, skincare) create durable competitive moats: third-party trust, premium positioning, B2B ingredient adoption, and diversified revenue channels that lessen reliance on any single retail or partner channel.
Bears Say
Weakening Operating Cash Flow / FCF VolatilitySharp deterioration in cash-flow growth and a Q1 operating cash use reflect working-capital strain from inventory builds and timing of partner orders; persistent cash volatility can limit reinvestment, constrain buybacks, or force higher external funding if growth accelerates.
Rising Operating Expenses Pressure MarginsManagement is deliberately increasing marketing and overhead to drive e‑commerce and launches, but higher customer acquisition and permanent G&A lifts reduce margin scalability. If competitor costs remain elevated, margin recovery may be delayed and returns on new spend uncertain.
Regulatory Uncertainty And Intensified NMN CompetitionRegulatory ambiguity and active litigation create a multi‑quarter risk to category dynamics. Rapid NMN entrant growth raises marketing costs and price competition, eroding share gains for NIAGEN and increasing the cost of new‑to‑brand acquisition, challenging long‑term growth economics.
Niagen Bioscience News
NAGE FAQ
What was Niagen Bioscience, Inc.’s price range in the past 12 months?
Niagen Bioscience, Inc. lowest stock price was $3.41 and its highest was $14.69 in the past 12 months.
What is Niagen Bioscience, Inc.’s market cap?
Niagen Bioscience, Inc.’s market cap is $274.77M.
When is Niagen Bioscience, Inc.’s upcoming earnings report date?
Niagen Bioscience, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 66 days.
How were Niagen Bioscience, Inc.’s earnings last quarter?
Niagen Bioscience, Inc. released its earnings results on May 06, 2026. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.068 by $0.002.
Is Niagen Bioscience, Inc. overvalued?
According to Wall Street analysts Niagen Bioscience, Inc.’s price is currently Undervalued.
Does Niagen Bioscience, Inc. pay dividends?
Niagen Bioscience, Inc. does not currently pay dividends.
What is Niagen Bioscience, Inc.’s EPS estimate?
Niagen Bioscience, Inc.’s EPS estimate is 0.02.
How many shares outstanding does Niagen Bioscience, Inc. have?
Niagen Bioscience, Inc. has 79,644,325 shares outstanding.
What happened to Niagen Bioscience, Inc.’s price movement after its last earnings report?
Niagen Bioscience, Inc. reported an EPS of $0.07 in its last earnings report, beating expectations of $0.068. Following the earnings report the stock price went down -15.694%.
Which hedge fund is a major shareholder of Niagen Bioscience, Inc.?
Currently, no hedge funds are holding shares in NAGE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Niagen Bioscience Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.25 (132.44% Upside)
$11.25 (132.44% Upside)
Blogger Sentiment
Bullish
NAGE Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 86.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.02%
12-Months-Change
Fundamentals
Return on Equity
25.38%
Trailing 12-Months
Asset Growth
40.56%
Trailing 12-Months
Company Description
Niagen Bioscience, Inc.
Niagen Bioscience Inc is a bioscience company dedicated to healthy aging. The Company leads research on nicotinamide adenine dinucleotide.
NAGE Company Deck
NAGE Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive tone: solid revenue and net income, strong e-commerce growth, margin stability, a robust cash position, and several strategic wins (USP monograph, new product launches, scientific leadership). Offsetting items include short-term cash flow drag from inventory and timing, higher selling/marketing and G&A investments, channel volatility with some distribution partners, and intensified competition and regulatory uncertainty around NMN which is creating headwinds. Management reaffirmed full-year guidance (10%–15% growth) while electing to invest in marketing and product rollouts to drive future growth.View all NAGE earnings summariesNAGE Stock 12 Month Forecast
Average Price Target
$11.25
▲(132.44% Upside)
Technical Analysis
Iovance Biotherapeutics
―
Kura Oncology
―
Vir Biotechnology
―
Fortrea Holdings Inc.
―
Septerna, Inc.
―
Ownership Overview
5.03% Insiders
8.39% Mutual Funds
9.08% Other Institutional Investors
69.46% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---